ACG1A; CEV14; GMAP210; TRIP-11; TRIP230; GMAP-210

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

The antibody detects endogenous levels of total TRIP11 protein.

Antigen affinity purification

Rabbit IgG in pH7.4 PBS, 0.05% NaN3, 40% Glycerol.

0.5mg/ml (lot specific)

Store at -20 degree C

Small volumes of anti-TRIP11 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

This gene was identified based on the interaction of its protein product with thyroid hormone receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis type IA.

Total protein Ab

Immunohistochemistry (IHC)

Immunohistochemistry: 1: 10-50

The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using TRIP11 Antibody at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: x200)

227,586 Da

thyroid hormone receptor interactor 11

thyroid receptor-interacting protein 11

Thyroid receptor-interacting protein 11

CEV14; TR-interacting protein 11; TRIP-11; GMAP-210??[Similar Products]

TRIPB_HUMAN

This gene was identified based on the interaction of its protein product with thyroid hormone receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis type IA.[provided by RefSeq, Mar 2010]

TRIP11: Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB- modulated transcription. Golgi auto-antigen; probably involved in maintaining cis-Golgi structure. A chromosomal aberration involving TRIP11 may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with PDGFRB. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia. Defects in TRIP11 are the cause of achondrogenesis type 1A (ACG1A). A form of achondrogenesis type 1, a lethal form of chondrodysplasia characterized by deficient ossification in the lumbar vertebrae and absent ossification in the sacral, pubic and ischial bones and clinically by stillbirth or early death. In addition to severe micromelia, there is a disproportionately large cranium due to marked edema of soft tissues.

Protein type: Nuclear receptor co-regulator; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 14q31-q32

Cellular Component: Golgi apparatus; Golgi membrane; nucleus; transport vesicle

Molecular Function: protein binding; transcription coactivator activity

Biological Process: transcription from RNA polymerase II promoter

Disease: Achondrogenesis, Type Ia

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.